Palvella Therapeutics Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scroll to see more
Palvella Therapeutics, Inc. income statement - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Revenue & Gross Profit
Revenue0.0042.3225.9031.4229.3246.2829.10
Cost of Revenue0.000.000.000.000.000.000.00
Gross Profit0.0042.3225.4731.4229.320.000.00
Operating Expenses
Research & Development8.158.7913.8866.6646.5355.0041.49
Selling, General & Administrative5.943.084.1616.5916.7118.4418.44
Operating Expenses14.1011.8718.0483.2563.2473.4459.93
Operating Income-14.10-11.87-18.04-51.83-33.92-27.16-30.83
Other Income/Expense
Interest Income0.006.270.000.000.001.711.96
Interest Expense4.320.00-10.360.000.000.000.00
Other Income/Expense-3.3424.30-0.17-5.88-1.76-0.031.80
Income
Income Before Tax-17.4318.69-28.58-49.42-37.07-25.47-27.07
Income Tax Expense0.000.00-1.030.000.160.00-0.31
Net Income-17.4318.69-27.55-45.74-37.20-25.47-26.75
Net Income - Continuous Operations-17.4318.69-27.550.000.000.000.00
Net Income - Discontinued Operations0.000.000.000.000.000.000.00
EBITDA-13.1218.69-18.04-46.96-34.94-26.12-30.26
EBIT-14.1018.69-18.04-49.42-37.07-27.16-30.83
Depreciation & Amortization0.001.802.302.402.100.000.00
Earnings Per Share
Basic EPS-8.002.00-5.00-1.00-1.00-1.00-
Diluted EPS-8.002.00-5.00-1.00-1.00-1.00-
Basic Shares Outstanding2.2311.225.7264.5554.4850.6353.08
Diluted Shares Outstanding2.2311.225.7264.5554.4850.6353.08